论文信息 - High levels of TNFα in patients with COVID-19 refractory to tocilizumab - 字舞流文

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

A. Marabelle | J. Michot | F. Ackermann | M. Roumier | F. Danlos | J. Rohmer

[1] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[2] I. Amit,et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 , 2020, Cell.

[3] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[4] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[5] P. Emery,et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[6] S. Baldovino,et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. , 2020 .

[7] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[8] Matthew Rowland,et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed , 2020, The Lancet.

[9] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.